We have previously shown that activation of the CXCR3 chemokine system plays a role in the immune response toward solid tumors and is predictive of therapy response.[35] Thus, the ability to engineer an immune activation of bespoke intensity paves a way toward exploiting mRNA‐induced CXCR3 ligand secretion in the context of tumor therapy, possibly to boost other regimens, such as CXCR3‐expressing CAR‐T cells against solid tumors. This evidence concerns the gene CXCR3 and neoplasm.